Using infliximab to treat colitis caused by immune checkpoint inhibitors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness and safety of infliximab, a TNF-alpha inhibitor, in combination with corticosteroids for patients experiencing severe immune-related colitis or diarrhea due to immune checkpoint inhibitors. Participants will be randomly assigned to receive either standard corticosteroid treatment or corticosteroids plus infliximab. The study will measure the time taken to achieve a reduction in colitis or diarrhea severity. Evaluations will include blood and fecal samples, as well as sigmoidoscopy assessments.

Why it matters

Who can join: the full rules

Inclusion Criteria

* Untreated mCTCAE grade 2-4 diarrhoea or colitis, or persistent mCTCAE grade 2 diarrhoea after administration of loperamide or equivalent for mCTCAE grade ≤ 2 diarrhoea
* No signs of colonic perforation or infection
* Age ≥ 18
* Understands the nature and purpose of the study and the study procedures and has signed informed consent
* Is able to read, understand, and complete questionnaires and daily components of the patient Diary for the study period
* Histologically confirmed malignant solid tumours
* Treatment with immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1 or anti-PD-L1) within the past 12 weeks. Immune checkpoint inhibitors can be administered as single agents or as combination therapy with anti-CTLA-4 and anti-PD-1
* No probability of a concomitant treatment (e.g. laxatives) other than the immune checkpoint inhibitor being the causal drug for the colitis or diarrhoea
* Prior treatment with immune checkpoint inhibitors is allowed
* Usage of prednisolone ≤ 10 mg daily for non irAE is allowed
* Diagnostic work up including screening for viral hepatic infection and QuantiFERON-TB for mycobacterium tuberculosis must be requisitioned but will not need to be reported prior to study enrolment
* Women of child bearing potential must have a negative serum (preferred) or urine pregnancy test within 72 hours prior to registration.

  * Note: women of childbearing potential are defined as premenopausal females capable of becoming pregnant (i.e. females who have had evidence of menses in the past 12 months, with the exception of those who had prior hysterectomy). However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, low body weight, ovarian suppression or other reasons.
* Patients of childbearing / reproductive potential should use adequate birth control measures, as defined by the investigator, during the study treatment period and after the study treatment:

  * for at least 6 months after the last study treatment, or depending on the duration antineoplastic treatment
  * Note: A highly effective method of birth control is defined as a method which results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly. Such methods include:

    * Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal)
    * Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)
    * Intrauterine device (IUD)
    * Intrauterine hormone-releasing system (IUS)
    * Bilateral tubal occlusion
    * Vasectomized partner
    * Sexual abstinence

Exclusion Criteria

* Prior history of inflammatory bowel disease, colitis, or diarrhoea requiring treatment with any corticosteroid, or any other immunosuppressant medication
* Prior history of recurrent bowel disease including symptomatic diverticulosis
* Current positive testing for Clostridium difficile or other colonic infection
* Current bacterial infection requiring antibiotic treatment, or systemic fungal infection
* Ongoing antibiotic treatment for any reason
* Treatment with systemic corticosteroids within the last four weeks prior to study enrolment (daily usage of prednisolone ≤ 10 mg for non irAE conditions is accepted)
* Concurrent immune-related adverse events requiring immunosuppressant medication of any kind
* Known hypersensitivity or contraindications to systemic corticosteroids or infliximab
* Prior history of viral hepatitis with a positive viral load, known untreated mycobacterium tuberculosis, or known active herpes zoster infection

Where it's running

• Department of Oncology Odense University Hospital
  Odense, Denmark Recruiting
• Department of Oncology, Aalborg University Hospital
  Aalborg, Denmark Not yet recruiting
• The Royal Marsden Hospital
  London, United Kingdom Not yet recruiting

Study contacts

• Principal investigator: Christina H. Ruhlmann, PhD — Department of Oncology, OUH
• Study coordinator: Sören K. Petersen, MD
• Email: soeren.kjaer@rsyd.dk
• Phone: 0045 2046 5726

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Single-dose MT-201 with Infliximab in healthy adults

  This early phase study tests a single dose of MT-201 given with infliximab in healthy adults to see if it is safe and how the body handles it.

  Recruiting Phase 1 Mirador Therapeutics, Inc. · San Diego, California · NCT07776782

• Infliximab plus prednisone vs prednisone alone for ICI-associated AKI

  This study tests whether adding infliximab to prednisone helps adults with kidney injury caused by cancer immunotherapy recover kidney function faster than standard prednisone alone.

  Recruiting at 2 sites Phase 4 Massachusetts General Hospital · Boston, Massachusetts and 2 other locations · NCT07683975

• Infliximab to Help Prevent CRS During Teclistamab or Talquetamab Therapy in Relapsed/Refractory Myeloma

  This phase 2 trial tests whether infliximab can prevent cytokine release syndrome in patients with relapsed or refractory multiple myeloma who are being treated with teclistamab or talquetamab.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07657312

• Upadacitinib versus infliximab for second-line treatment of acute severe ulcerative colitis

  This trial will see if upadacitinib or infliximab works better to induce remission in adults with acute severe ulcerative colitis who need second-line therapy.

  Recruiting at 4 sites Phase 4 Xijing Hospital of Digestive Diseases · Ankang, Shaanxi and 3 other locations · NCT07550673

• Guselkumab in Ulcerative Colitis and Crohn’s Disease in Saudi Arabia: Real-World Use

  This study looks at how long people with moderate-to-severe Crohn’s disease or ulcerative colitis continue taking guselkumab in everyday clinical practice in Saudi Arabia.

  Recruiting Janssen Research & Development, LLC · Jeddah · NCT07541261

• Infliximab level monitoring in children with inflammatory bowel disease

  This project will test whether measuring infliximab levels in saliva and leftover blood during the first infusions helps monitor and personalize treatment for children and teens (ages 3–18) with Crohn's disease or ulcerative colitis.

  Recruiting Meyer Children's Hospital IRCCS · Florence, Italy · NCT07470502

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.